Royal Marsden NHS Foundation Trust: Neoplasms trials

The registry lists 14 Neoplasms studies with Royal Marsden NHS Foundation Trust as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 1Phase 2 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Body Composition in Older AdultsNot yet recruitingNCT06630754
• Understanding immunE-related toXicities by multifACeT ProfilingRecruitingNCT05331066
• Value of Analysing Under-utilised Leftover Tissue (VauLT)RecruitingNCT03832062
• Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)CompletedNCT04427280Results posted
• Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833CompletedNCT02437227Phase 1Results posted
• Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid BiopsiesCompletedNCT04566614
• Information Needs Around Parenteral nUTrition in CancerCompletedNCT04495530
• Developing a Symptom List for Children With CancerStatus unknownNCT02726815
• Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic RadiotherapyStatus unknownNCT02649491
• Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and ImagingCompletedNCT02486094
• Low Rectal Cancer Study (MERCURY II)Status unknownNCT02005965
• Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) TrialStatus unknownNCT01995942
• Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 WeeksStatus unknownNCT01037049Phase 2
• Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 InhibitorStatus unknownNCT01024283